Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00672919 · ClinicalTrials.gov registry record · Phase 4

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

A Phase 4 study of Diabetes Mellitus, sponsored by Takeda.

Completed
Registry status
Phase 4
Development phase
305
Enrollment target
20
Study locations

NCT00672919: Completed Phase 4 study of Diabetes Mellitus, sponsored by Takeda.

NCT00672919 is a Phase 4 study of Diabetes Mellitus that has completed, run by Takeda. The registered enrollment target is 305 participants, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00672919, a Phase 4 study of Diabetes Mellitus, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 4
Development phase
305 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to measure the triglyceride changes in subjects with type 2 diabetes mellitus taking pioglitazone, once daily (QD), following treatment conversion from rosiglitazone.

Conditions Studied

Interventions

  • DRUG Pioglitazone

Study Locations (20)

Florida

  • - Aventura
  • - Hollywood
  • - Jacksonville
  • - Miami
  • - North Miami Beach
  • - Tallahassee
  • - West Palm Beach

California

  • - Bellflower
  • - Burlingame
  • - Fresno
  • - La Jolla
  • - Long Beach
  • - Pasadena

Connecticut

  • - Norwalk
  • - Waterbury

Alabama

  • - Birmingham

Arizona

  • - Tucson

Colorado

  • - Arvada

Georgia

  • - Columbus

Idaho

  • - Idaho Falls

Trial Details

FieldValue
Enrollment Target 305 participants
Start Date 2003-11
Est. Completion 2004-08
Phase Phase 4
Takeda

408 total trials

What the finished NCT00672919 record still lists

NCT00672919 is an interventional study that assigns participants to a tested intervention. The registered 305 participants enrollment target is mid-sized for trials with a published cap, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (84% lower).

The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Pioglitazone is the first listed.

NCT00672919 names 20 study sites across 8 states, led by Florida, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00672919 about?

NCT00672919 is a clinical study titled "Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.". The purpose of this study is to measure the triglyceride changes in subjects with type 2 diabetes mellitus taking pioglitazone, once daily (QD), following treatment conversion from rosiglitazone.

What is the current status of trial NCT00672919?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 305 participants. The study started on 2003-11. Estimated completion is 2004-08.

What conditions does trial NCT00672919 study?

This clinical trial studies the following conditions: Diabetes Mellitus.

What interventions are being tested in trial NCT00672919?

The interventions under investigation include: Pioglitazone (DRUG).

Who is sponsoring clinical trial NCT00672919?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00672919 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00672919's enrollment target sits among peer trials

305 63rd of 208 higher than 145 of 208 other Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04107181 · 305 participants · NA

    Pilot Study for Speculum Free Cervical Cancer Screening

  • NCT05399056 · 305 participants · NA

    Improving Participation in Pulmonary Rehabilitation Through Peer Support and Storytelling

  • NCT05078970 · 306 participants · NA

    Advancing Suicide Intervention Strategies for Teens During High Risk Periods

  • NCT05843695 · 306 participants · NA

    Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00672919, the US trial registry maintained by the National Library of Medicine. NCT00672919 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.